To include your compound in the COVID-19 Resource Center, submit it here.

M&A crystal ball

At least six biotech companies will disappear as the result of M&A activity last week, leading some to wonder whether the oft-talked about consolidation is upon us. The answer: don't bank on it. Even though there is a horde of hungry mouths and little sign that a window will open, market watchers polled by Ebb & Flow point out that the big, strategic buyers - pharma and profitable biotech - remain cautious about dinging EPS. And with valuations still in flux, it's hard to peg what some companies are worth.

Lazard banker David Low

Read the full 930 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE